000 03212nam a22004815i 4500
001 978-1-4471-5424-2
003 DE-He213
005 20140220082456.0
007 cr nn 008mamaa
008 131004s2014 xxk| s |||| 0|eng d
020 _a9781447154242
_9978-1-4471-5424-2
024 7 _a10.1007/978-1-4471-5424-2
_2doi
050 4 _aRC681-688.2
072 7 _aMJD
_2bicssc
072 7 _aMED010000
_2bisacsh
082 0 4 _a616.12
_223
100 1 _aAvanzas, Pablo.
_eeditor.
245 1 0 _aPharmacological Treatment of Acute Coronary Syndromes
_h[electronic resource] /
_cedited by Pablo Avanzas, Peter Clemmensen.
264 1 _aLondon :
_bSpringer London :
_bImprint: Springer,
_c2014.
300 _aXVI, 245 p. 24 illus., 12 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Cardiovascular Therapy
505 0 _aForeword -- Preface -- Anti-ischemic Therapy -- Antiaggregant Therapy: New potent P2Y12 inhibitors -- Anticoagulation Therapy: Heparins and Factor Xa inhibitors -- Secondary prevention in ACS The role of novel oral anticoagulants -- American vs European guidelines -- Critical appraisal -- Triple therapy: Risky but sometimes necessary -- Management of bleeding complications.
520 _aThis book updates clinicians on the most recent data regarding the medical management of patients of acute coronary syndrome (ACS), providing useful information and expert opinion on the large trials, international guidelines, and clinical practice. It reinforces the need for rapid intervention with pharmacologic therapies to treat and prevent coronary thromboembolism, and to prepare the patient for revascularization procedures, especially percutaneous coronary intervention. Pharmacological Treatment of Acute Coronary Syndromes describes conventional treatment – including anti-ischemic, antiplatelet and anticoagulant therapy – and discusses the clinical use of newer treatment options: the potent new P2Y12 platelet receptor inhibitors with the recently recommended ticagrelor and prasugrel, and new oral anticoagulant agents showing promise for acute management and secondary prevention in ACS. Triple therapy, while not initiated in the acute setting, may impact on future surgical and medical emergencies and their management. Also covered are the various recommendations for each of the antiplatelet and anticoagulant agents in terms of patient selection, pretreatment and timing of therapy, making this book an essential read for a wide range of health professionals.
650 0 _aMedicine.
650 0 _aPharmacy.
650 0 _aCardiology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aCardiology.
650 2 4 _aPharmacy.
650 2 4 _aPharmacotherapy.
700 1 _aClemmensen, Peter.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781447154235
830 0 _aCurrent Cardiovascular Therapy
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4471-5424-2
912 _aZDB-2-SME
999 _c91883
_d91883